Product Information for the User
ERITROMYCIN OINTMENT 5 mg/g Ophthalmic Ointment
Erithromycin
Read this entire product information carefully before starting to use this medication, as it contains important information for you.
This is an ophthalmic ointment (for the eyes) that contains an antibiotic (erythromycin), which acts against certain microorganisms that cause eye infections.
Antibiotics are used to treat bacterial infections and do not work for viral infections.
It is essential that you follow the instructions regarding the dose, administration interval, and treatment duration indicated by your doctor.
Do not store or reuse this medication. If you have leftover antibiotic after treatment, return it to the pharmacy for proper disposal. Do not dispose of medications through the drain or in the trash.
This medication is used for the treatment of superficial eye infections caused by microorganisms sensitive to erythromycin; and as a preventive treatment for newborn conjunctivitis (ophthalmia neonatorum).
Do not use Oftalmolosa Cusí Eritromicina
If you are allergic to erythromycin or to any of the other components of this medication (listed in section 6).
Warnings and precautions
Consult your doctor or pharmacist before starting to use Oftalmolosa Cusí Eritromycin.
Only use this medication in your eye(s).
If you use this medication for a long period of time or in excess, you may become more sensitive to other eye infections, including fungal infections. Consult your doctor if your symptoms worsen or return suddenly.
If you use contact lenses:
-Wearing contact lenses (hard or soft) is not recommended during eye infection treatment.
Other medications and Oftalmolosa Cusí Eritromycin
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medication.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication. This medication is not recommended during pregnancy.
During breastfeeding, decide whether to interrupt it or interrupt the treatment with this medication after considering the benefits of breastfeeding for the child and the benefits of treatment for the mother.
Driving and operating machines
You may notice blurred vision immediately after applying Oftalmolosa Cusí Eritromycin. Do not drive or operate machines until this effect has disappeared.
Follow exactly the administration instructions of this medication as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
The recommended dose is:
Adults and children
For the treatment of superficial eye infections: Apply approximately 1cm of ointment to the affected eye(s) one or more times a day, according to the severity of the infection (up to a maximum of 6 times a day).
Newborns
A single application is sufficient for the preventive treatment of neonatal conjunctivitis.
Usage recommendations:
- 2 -
If you are using other eye medications, wait at least 5 minutes between the administration of this ointment and the other eye medications. Eye ointments should be administered last.
If you use more Oftalmolosa Cusí Eritromicina than you should
A overdose in the eyes can be eliminated by rinsing the eyes with warm water. Do not apply more ointment until the next dose.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service. Phone 91 562 04 20, indicating the medication and the amount used.
If you forgot to use Oftalmolosa Cusí Eritromicina
Do not apply a double dose to compensate for the missed doses.
Apply it as soon as you remember and continue with the next dose that was scheduled. However, if it is almost time for the next dose, do not apply the missed dose and continue with the next dose of your regular regimen.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication may produce adverse effects, although not all people may experience them.
The following adverse reactions of unknown frequency have been observed with this medication:(cannot be estimated from the available data):
General effects: mild allergic reaction (hypersensitivity), mild eye irritation, and redness; burning sensation.
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect not listed in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicinal Products for Human Use:https://www.notificaram.es.Reporting adverse effects can help provide more information about the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the tube and on the box after CAD. The expiration date is the last day of the month indicated.
Do not store at a temperature above 25°C.
To prevent infections, discard the tube 4 weeks after first opening it.
Record the date of opening the tube in the reserved box for this purpose.
Medications should not be thrown down the drains or in the trash. Deposit the containers and medications you do not need at the SIGRE collection point of the pharmacy. If in doubt, ask your pharmacist how to dispose of the containers and medications you do not need. By doing so, you will help protect the environment.
Appearance of the product and contents of the packaging
Oftalmolosa Cusí Erythromycin is an eye ointment (for use in the eyes), a whitish paste, presented in an aluminum tube containing 3.5 g with a polyethylene plug.
Holder of the marketing authorization:
NTC S.r.l.
Via Luigi Razza, 3
20124 Milan, Italy
Responsible for manufacturing
Siegfried El Masnou, S.A.
C/ Camil Fabra, 58
08320 El Masnou – Barcelona, Spain.
You can request more information about this medication by contacting the local representative of the holder of the marketing authorization:
NTC Ophthalmics Ibérica, S.L.
Calle Pinar 5
28006 Madrid, Spain
Date of the last review of this leaflet:January 2020.
The detailed information about this medication is available on the website of the Spanish Agency of Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.